Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director · Chief Executive Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,048,485 |
Ending reported balance
After 2026-09-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Exercise / conversion · Acquired 392,157 · Balance 2,124,026 Row 2 · 2026-09-09 · Tax withholding · Disposed 75,541 · Balance 2,048,485 F1: The Reporting Person paid the exercise price of the Warrant on a cashless basis. The Issuer withheld 75,541 shares, calculated in accordance with the terms of the Warrant, to pay the exercise price and issued the remaining 316,616 shares to the Reporting Person. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2030-03-25 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-09 · Exercise / conversion · Disposed 392,157 · Balance 0 F2: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person paid the exercise price of the Warrant on a cashless basis. The Issuer withheld 75,541 shares, calculated in accordance with the terms of the Warrant, to pay the exercise price and issued the remaining 316,616 shares to the Reporting Person.
F2: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 20:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Exercise / conversionWarrant (right to buy) · Derivative | 392,157 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001140361-26-036347 · form4.xml · derivative · entry 3 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 392,157 shares Expires 2030-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 75,541 | $5.97 | $450,979.77 |
DisclosureSEC source: 0001140361-26-036347 · form4.xml · nonDerivative · entry 2 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,048,485 F1 · kind: The Reporting Person paid the exercise price of the Warrant on a cashless basis. The Issuer withheld 75,541 shares, calculated in accordance with the terms of the Warrant, to pay the exercise price and issued the remaining 316,616 shares to the Reporting Person. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:09 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Exercise / conversionCommon Stock | 392,157 | $1.15 | $450,980.55 |
DisclosureSEC source: 0001140361-26-036347 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,124,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:07 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 9,475 | $2.95 | $27,925.67 |
DisclosureSEC source: 0000905148-26-003352 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,731,869 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $2.9009 to $3.025, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 20:27 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 9,511 | $5.22 | $49,647.42 |
DisclosureSEC source: 0000905148-26-001864 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,741,344 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:10 UTC | Opus Genetics, Inc. IRD · Entity 5892 | SaleCommon Stock | 24,438 | $5.21 | $127,326.87 |
DisclosureSEC source: 0000905148-26-001381 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750,855 F1 · kind: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. F2 · price: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.21 to $5.215, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2026 Filed Jan 27, 2026 00:48 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 483,639 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000356 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775,293 F1 · shares: Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 21:22 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 30,350 | $2.30 | $69,805.00 |
DisclosureSEC source: 0000905148-25-003767 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,291,654 Read SEC document |
| November 01, 2025 Filed Nov 5, 2025 21:06 UTC Amendment | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 30,350 | $2.30 | $69,805.00 |
DisclosureSEC source: 0000905148-25-003777 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,291,654 F1 · kind: The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:10 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantWarrants (right to buy) · Derivative | 392,157 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0000905148-25-001007 · form4.xml · derivative · entry 2 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,157 Underlying: Common Stock · 392,157 shares Expires 2030-03-24 F1 · kind: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F1 · price: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F2 · derivative.exercise_date: These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:10 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 392,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-001007 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,322,004 F1 · kind: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F1 · price: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:53 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 330,697 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000905148-25-000940 · form4.xml · derivative · entry 2 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,697 Underlying: Common Stock · 330,697 shares Expires 2035-03-12 F2 · derivative.exercise_date: The option will vest with respect to 25% on March 13, 2026, with the remaining shares vesting quarterly in 12 equal installments thereafter at the end of each quarter, subject to the Reporting Person's continuing service. Read SEC document |
| March 13, 2025 Filed Mar 18, 2025 00:53 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 330,697 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000940 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,847 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of March 13, 2025, subject to the Reporting Person's continuing service. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:26 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 100,000 | $0.98 | $97,600.00 |
DisclosureSEC source: 0000905148-24-003425 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,150 F1 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.97 to $0.98, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 22:50 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-003406 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,150 F1 · kind: These shares were issued to the Reporting Person to correct an inadvertent over-withholding of shares on November 1, 2024, in connection with the vesting of restricted stock units on that date. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:08 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 9,706 | $1.02 | $9,942.83 |
DisclosureSEC source: 0000905148-24-003236 · form4.xml · nonDerivative · entry 2 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,950 F2 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.005 to $1.06, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:08 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 90,294 | $1.01 | $91,215.00 |
DisclosureSEC source: 0000905148-24-003236 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,244 F1 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.975 to $1.05, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:13 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Tax withholdingCommon Stock | 37,050 | $1.18 | $43,719.00 |
DisclosureSEC source: 0000905148-24-002934 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,950 Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:18 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 5,000 | $1.75 | $8,772.50 |
DisclosureSEC source: 0000905148-24-001568 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,000 F1 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.73 to $1.78, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:18 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 25,000 | $1.96 | $49,050.00 |
DisclosureSEC source: 0000905148-24-000991 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 F1 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.90 to $1.99, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 13:29 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001140361-23-051320 · form4.xml · derivative · entry 2 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-10-31 F2 · derivative.exercise_date: The option will vest with respect to 25% on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments on the last day of each full month over the subsequent 36 months, subject to continuing service. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 13:29 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-051320 · form4.xml · nonDerivative · entry 1 Magrath George · CIK 0001999390 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of November 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.